School of Medicine
Showing 141-160 of 318 Results
-
David B. Lewis
Naddisy Foundation Professor of Pediatric Food Allergy, Immunology, and Asthma
Current Research and Scholarly InterestsMy laboratory is focused on defining cellular and molecular mechanisms that limit T cell responses to vaccines and pathogens during normal early postnatal development and in cases of inherited genetic immunodeficiencies. We are also determinomg how these limitations in immunity can be overcome by using novel approaches for vaccine adjuvants for influenza vaccine and by using catalytically inactive Cas proteins for inducing endogenous gene expression.
-
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Matthew Lewis, MD, MPH
Clinical Associate Professor, Dermatology
BioDr. Lewis specializes in autoimmune connective tissue diseases, immunobullous diseases, and other inflammatory skin diseases including psoriasis and sarcoidosis. He completed medical school at The George Washington University School of Medicine and dermatology residency at The University of Rochester, where he was chief resident. He also completed a Master’s of Public Health at Johns Hopkins and a fellowship in autoimmune connective tissue diseases at Stanford University.
He believes multidisciplinary and holistic care is key to treat patients with systemic inflammatory diseases. He holds a rheumatology-dermatology clinic with a rheumatologist, Dr. Janice Lin, as well as a dermatology-ophthalmology clinic with an ophthalmologist, Dr. Christopher Ta, and is the dermatologist for the sarcoidosis program, all with this primary goal of providing high quality, collaborative, patient-centered care. -
Richard Lewis
Professor of Molecular and Cellular Physiology, Emeritus
Current Research and Scholarly InterestsWe study molecular mechanisms of calcium signaling with a focus on store-operated CRAC channels and their essential roles in T cell development and function. Currently we aim to define the molecular mechanism for CRAC channel activation and the means by which calcium signal dynamics mediate specific activation of transcription factors and T-cell genes during development.
-
William Spencer Lewis, MD
Clinical Assistant Professor, Otolaryngology (Head and Neck Surgery)
BioA native of the south Bay Area, Dr. Lewis brings 25 years of professional experience in the field of otolaryngology. He graduated with highest honors from UC Davis in biochemistry, and he was elected to the Alpha Omega Alpha Honor Society at the University of Southern California School of Medicine. He is Board Certified in Otolaryngology, a Qualified Medical Evaluator, a licensed Hearing Aid Dispenser, and a licensed X-Ray Supervisor/Operator. Dr. Lewis is honored to be past-president of the Santa Clara County Medical Association and past Chief of the Medical Staff at Good Samaritan Hospital.
Dr. Lewis treats both children and adults for general ear, nose and throat diseases. He has a special interest in hearing and balance problems, including chronic ear infections, sudden hearing loss, balance problems and vertigo.
When not working, Dr. Lewis has an eclectic mix of interests. He enjoys sporting events and activities, including running, swimming, cycling, golfing and basketball. He finds satisfaction in do-it-yourself home projects, especially woodworking. Above all, he loves to get out into the great outdoors and commune with nature. -
Daniel Yuhang Li
Instructor, Medicine - Cardiovascular Medicine
BioI am a physician scientist in the Division of Cardiology at Stanford. My clinical interest is at the intersection of inflammation, autoimmunity and cardiovascular disease in a field called 'Cardio-Rheumatology'. Patients with rheumatologic diseases typically have an elevated cardiovascular disease risk profile along with an insidious onset. Moreover, with the ever-expanding biologic drug formulary for patients, it is important for us to characterize the cardiovascular effects of these medications. In my research, I believe that understanding how inflammatory and autoimmune mechanisms modify coronary artery disease can help us develop a novel perspective towards treating atherosclerosis beyond lipid lowering. My research goal is to advance novel therapeutics for atherosclerosis by leveraging my expertise in genetics, computational biology, and experience with diverse model organism perturbation models. My strategy employs a ‘systems’ approach, starting with human population variations at the genetic level and integrating findings across RNA, protein, and model organism studies. This comprehensive synthesis aims to grasp the overarching biological narrative, thereby facilitating the development of translational therapies that transform concepts from bench to bedside.
-
Dayan Li
Clinical Scholar, Dermatology
Postdoctoral Scholar, Pediatric SurgeryCurrent Research and Scholarly InterestsWound healing, cutaneous fibrosis
-
Gordon Li, MD
Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly Interests1.) My laboratory studies the biology of brain tumors with the goal of developing novel therapeutics for the treatment of malignant brain tumors and translating that research into clinical trials.
2.) My clinical interests include improving surgical techniques for brain tumor surgery, immunotherapy for the treatment of glioblastoma, and novel uses for stereotactic radiosurgery. -
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
Lingyin Li
Associate Professor of Biochemistry
BioDr. Li is an associate professor in the Biochemistry Department and ChEM-H Institute at Stanford since 2015. Her lab works on understanding biochemical mechanisms of innate immunity and harnessing it to treat cancer. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology.
-
Ron Li
Clinical Associate Professor, Medicine
BioRon Li is a Clinical Associate Professor of Medicine in the Division of Hospital Medicine and Center for Biomedical Informatics Research at Stanford University School of Medicine. As the Medical Informatics Director for Digital Health at Stanford Health Care, he provides medical and informatics direction for the health system's enterprise digital health portfolio, including expanding digital referral networks and virtual care modalities. He is the co-founder and Director for the Stanford Emerging Applications Lab (SEAL), which helps clinicians and staff build ideas into novel digital products that are prototyped and tested for care delivery at Stanford Health Care.
Ron's academic interests focus on the "delivery science" of new technological capabilities such as digital and artificial intelligence in healthcare and how to design, implement, and evaluate new tech enabled models of care delivery. Ron's work spans across multiple disciplines, including clinical medicine, data science, digital health, information technology, design thinking, process improvement, and implementation science. He has consulted for various companies in the digital health and artificial intelligence space. He is an attending physician on the inpatient medicine teaching service at Stanford Hospital and is the Associate Program Director for the Stanford Clinical Informatics Fellowship. -
Ruijiang Li
Associate Professor (Research) of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsMy lab's research is focused on the development of imaging and molecular biomarkers to improve cancer detection, diagnosis, prognostication, and prediction of therapy response. Our ultimate goal is to translate these biomarkers into clinical practice to guide optimal management and therapeutic decisions for precision cancer medicine.
